Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golidocitinib plus Anti-PD-1 in Advanced NSCLC
NCT06690671Phase 2Not yet recruiting
- Sponsor
- Shanghai Chest Hospital
- Start
- Dec 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of golidocitinib in non-small cell lung cancer (NSCLC), sponsored by Shanghai Chest Hospital. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
golidocitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06690671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06690671.